Short answer
Atea Pharmaceuticals, Inc. (AVIR) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$45M
- −32.6% YoY
- EPS (diluted)
- −$0.57
- −42.5% YoY
Source: XBRL data from the Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 10-Q on SEC EDGAR. USD.
Atea Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved or product revenue since inception
- Net loss $45.4M vs $34.3M YoY; operating loss $48.0M vs $39.0M
- HCV external R&D $29.3M vs $17.6M; HEV external R&D $4.0M vs $0
- Cash, equivalents and marketable securities $256.0M; operating cash use $46.4M
- C-BEYOND topline results expected mid-2026; C-FORWARD results at year-end 2026, NDA targeted March 2027
Risk Factors
- No newly added risk factor identified; provided section is truncated and contains no 10-K comparison
- Clinical concentration risk: HCV regimen requires successful Phase 3 completion before regulatory submission or commercialization
- Regulatory risk: FDA or foreign authorities may require additional trials or studies before approving HCV or HEV candidates
- Near-term operational risk: HCV Phase 3 costs exceed Phase 2 costs because of larger enrollment and an active comparator
- Liquidity risk: $48.0 million quarterly operating expenses and $568.0 million accumulated deficit amid no product revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Atea Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.